Cardiovascular Medicines Approved in the EU (EMA)

• 122medicines authorised in the EU (authorised now)

Each number has its full source under its own list below.

• 29May2026

  Bopediat

  Active substance: furosemide

  EMEA/H/C/006617
• 12Feb2026

  Myqorzo

  Active substance: aficamten

  EMEA/H/C/006228
• 21Nov2025

  Svariya (previously Rivaroxaban Koanaa)

  Active substance: rivaroxaban

  EMEA/H/C/006643
• 10Feb2025

  Beyonttra

  Active substance: acoramidis hydrochloride

  EMEA/H/C/006333
• 22Aug2024

  Eurneffy

  Active substance: epinephrine

  EMEA/H/C/006139
• 1Aug2024

  Adzynma

  Active substance: rADAMTS13

  EMEA/H/C/006198
• 27May2024

  Neoatricon

  Active substance: dopamine hydrochloride;Dopamine

  EMEA/H/C/006044
• 19Feb2024

  Dabigatran etexilate Teva (previously Dabigatran etexilate Leon Farma)

  Active substance: dabigatran etexilate mesilate

  EMEA/H/C/005922
• 16Feb2024

  Vlustozik (previously Ibuprofen Gen.Orph)

  Active substance: Ibuprofen

  EMEA/H/C/006129
• 15Nov2023

  Aqumeldi

  Active substance: Enalapril (maleate)

  EMEA/H/C/005731
• 26Jun2023

  Camzyos

  Active substance: Mavacamten

  EMEA/H/C/005457
• 26May2023

  Qaialdo

  Active substance: spironolactone

  EMEA/H/C/005535
• 26May2023

  Dabigatran Etexilate Accord

  Active substance: dabigatran etexilate mesilate

  EMEA/H/C/005639
• 24Mar2023

  Dapagliflozin Viatris

  Active substance: dapagliflozin

  EMEA/H/C/006006
• 31May2022

  Zolsketil pegylated liposomal

  Active substance: doxorubicin hydrochloride, liposomal

  EMEA/H/C/005320

Source: European Medicines Agency, Centrally authorised human medicines (EPAR), authorised now. Retrieved 12 Nov 2026.

• Chance of dying 30–70 from heart disease, cancer, diabetes or lung disease
• Clinical trials: Heart and blood vessels
• Medicine sales: heart and blood vessels
• Heart disease death rate

• Stroke
• Diabetes
• Hypertension
• Respiratory
• Pediatric
• Brain and nerves
• Obesity
• Women's health
• HIV